Discovery and optimization of a novel spiropyrrolidine inhibitor of {beta}-secretase (BACE1) through fragment-based drug design.
Efremov, I.V., Vajdos, F.F., Borzilleri, K.A., Capetta, S., Chen, H., Dorff, P.H., Dutra, J.K., Goldstein, S.W., Mansour, M., McColl, A., Noell, S., Oborski, C.E., O'Connell, T.N., O'Sullivan, T.J., Pandit, J., Wang, H., Wei, B., Withka, J.M.(2012) J Med Chem 55: 9069-9088
- PubMed: 22468999 
- DOI: 10.1021/jm201715d
- Primary Citation of Related Structures:  
3UDR, 3UDY, 3UDJ, 3UDK, 3UDM, 3UDN, 3UDP, 3UDQ, 3UDH - PubMed Abstract: 
The aspartyl protease β-secretase, or BACE, has been demonstrated to be a key factor in the proteolytic formation of Aβ-peptide, a major component of plaques in the brains of Alzheimer's disease (AD) patients, and inhibition of this enzyme has emerged as ...